Allspring Global Investments Holdings LLC Increases Stock Holdings in Sanofi (NASDAQ:SNY)

Allspring Global Investments Holdings LLC boosted its stake in shares of Sanofi (NASDAQ:SNY) by 128.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 115,330 shares of the company’s stock after buying an additional 64,747 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Sanofi were worth $5,558,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Franklin Resources Inc. raised its holdings in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Natixis Advisors LLC grew its position in Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock valued at $165,640,000 after buying an additional 114,133 shares during the last quarter. JPMorgan Chase & Co. grew its position in Sanofi by 20.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after buying an additional 399,301 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock valued at $110,715,000 after acquiring an additional 664,455 shares during the period. Finally, Jennison Associates LLC lifted its holdings in Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock valued at $109,753,000 after acquiring an additional 1,720,972 shares during the period. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Trading Down 0.6 %

Sanofi stock opened at $53.60 on Thursday. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The stock has a market capitalization of $136.03 billion, a PE ratio of 21.53, a price-to-earnings-growth ratio of 1.02 and a beta of 0.57. The firm has a 50 day simple moving average of $50.65 and a 200-day simple moving average of $52.49. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. As a group, equities research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.